A detailed history of Assenagon Asset Management S.A. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 969 shares of MDGL stock, worth $313,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares
969
Previous 5,831 83.38%
Holding current value
$313,219
Previous $1.63 Million 87.45%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$212.22 - $292.96 $1.03 Million - $1.42 Million
-4,862 Reduced 83.38%
969 $205,000
Q2 2024

Jul 18, 2024

SELL
$193.33 - $291.99 $1.38 Million - $2.08 Million
-7,127 Reduced 55.0%
5,831 $1.63 Million
Q1 2024

Apr 24, 2024

SELL
$171.37 - $283.23 $1.05 Million - $1.73 Million
-6,124 Reduced 32.09%
12,958 $3.46 Million
Q4 2023

Jan 17, 2024

SELL
$120.4 - $237.13 $2.8 Million - $5.52 Million
-23,294 Reduced 54.97%
19,082 $4.42 Million
Q3 2023

Nov 06, 2023

SELL
$146.04 - $225.78 $62 Million - $95.8 Million
-424,390 Reduced 90.92%
42,376 $6.19 Million
Q2 2023

Jul 25, 2023

SELL
$203.88 - $312.0 $10.2 Million - $15.5 Million
-49,822 Reduced 9.64%
466,766 $108 Million
Q1 2023

Apr 18, 2023

BUY
$231.06 - $307.08 $90.6 Million - $120 Million
392,145 Added 315.12%
516,588 $125 Million
Q4 2022

Jan 12, 2023

BUY
$58.39 - $296.54 $6.73 Million - $34.2 Million
115,234 Added 1251.32%
124,443 $36.1 Million
Q2 2022

Jul 27, 2022

BUY
$58.04 - $100.2 $534,490 - $922,741
9,209 New
9,209 $659,000
Q2 2021

Jul 15, 2021

SELL
$97.2 - $137.59 $1.56 Million - $2.21 Million
-16,098 Closed
0 $0
Q1 2021

Apr 26, 2021

BUY
$108.54 - $125.2 $1.75 Million - $2.02 Million
16,098 New
16,098 $1.88 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.53B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Assenagon Asset Management S.A. Portfolio

Follow Assenagon Asset Management S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.